Emergent BioSolutions Inc. 4
4 · Emergent BioSolutions Inc. · Filed Jul 2, 2007
Insider Transaction Report
Form 4
Keese Kyle
SVP, Mfg Ops
Transactions
- Sale
Common Stock
2007-06-28$9.69/sh−1,446$14,012→ 7,121 total - Exercise/Conversion
Employee Stock Option (right to buy)
2007-06-29−1,445→ 0 totalExercise: $2.74Exp: 2007-06-30→ Common Stock (1,445 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2007-06-28−1,446→ 1,445 totalExercise: $2.74Exp: 2007-06-30→ Common Stock (1,446 underlying) - Sale
Common Stock
2007-06-29$9.93/sh−1,250$12,413→ 7,316 total - Exercise/Conversion
Common Stock
2007-06-29$2.74/sh+1,445$3,959→ 8,566 total - Exercise/Conversion
Common Stock
2007-06-28$2.74/sh+1,446$3,962→ 8,567 total
Footnotes (3)
- [F1]The option became fully vested on December 31, 2006 and will expire on June 30, 2007.
- [F2]Reflects the average sales price of shares sold by Merrill Lynch on such date in its administration of Rule 10b5-1 trading plans for Emergent BioSolutions Inc. common stock. These shares were sold at prices ranging from $9.58 to $9.85 per share.
- [F3]Reflects the average sales price of shares sold by Merrill Lynch on such date in its administration of Rule 10b5-1 trading plans for Emergent BioSolutions Inc. common stock. These shares were sold at prices ranging from $9.78 to $10.06 per share.